Biogen has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts, useful in treating disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1). The patent also covers methods for their production and use. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of May 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11999715B2) discloses a compound of Formula (I) and its various derivatives represented by Formulas (III) and (IV). The compounds described in the patent have specific structural features, including substituents R1, R2, R3, and R4, which are defined in detail in the claims. These compounds are intended for use in pharmaceutical compositions for treating disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1) in subjects. The patent also covers methods of treating various disorders such as neurodegenerative disorders, cardiovascular diseases, inflammatory diseases, autoimmune disorders, and cancer by administering the disclosed compounds or their pharmaceutically acceptable salts.
Furthermore, the patent encompasses a pharmaceutical composition comprising the disclosed compounds and a pharmaceutically acceptable excipient. The compounds described in the patent are specifically designed to target ASK1 inhibition, making them potentially valuable in the treatment of a wide range of conditions, including metabolic disorders, pain, kidney fibrosis, liver diseases, and respiratory diseases. The patent's claims provide a detailed description of the chemical structures and substituents that define the compounds, emphasizing their potential therapeutic applications in diverse medical conditions. The patent's scope extends to the use of these compounds in the treatment of disorders where ASK1 inhibition plays a crucial role, highlighting their significance in the development of novel therapeutic interventions.
To know more about GlobalData’s detailed insights on Biogen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
